Georgia Bio Members Take Advantage of the Abundant Networking and Partnering Opportunities at BIO 2019

Georgia Bio was delighted to attend the 2019 BIO International Convention in Philadelphia from June 3rd to June 6th. During the four days of programming and exhibitions under the theme, “It Starts with One,” Georgia Bio and some of its members had the opportunity to continue their mission of advancing the growth of Georgia’s life science industry by fostering new and existing relationships with like-minded organizations. 

The 2019 BIO International Convention included 126 educational sessions, more than 800 speakers, over 250 company presentations, 1,800 exhibitors, and plenty of networking and partnering opportunities. Among the 17,300 attendees at this year’s event were both Georgia life science companies and Georgia Bio members, PainCareLabs and Recro Gainesville.

Dr. Amy Baxter, founder and CEO of PainCareLabs in Atlanta, spoke positively about her experience exhibiting at the 2019 Convention and on the support that the State of Georgia was able to provide their affiliated companies that allowed them to take full advantage of their time at the convention. 

“Georgia did everything right,” explained Baxter. “They had a gorgeous booth, offered strong support so we could focus on networking, and executed great planning in advance.

“It may seem odd to be a medical device company at a bio/pharma event, but our devices work in conjunction with pharma products to block the pain of their injections and everyone was interested in how we could make the patient journey better for their patients. The explosion in the biosimilars market means companies want a way to differentiate their product and support.” 

Amy also noted that the female to men ratio at Convention was significantly higher compared to other industry conferences that she has attended, including J.P. Morgan, and there were several female CEOs that visited their booth. This year, BIO was able to break their own Guinness World Record for “The Largest Business Partnering Event” – previously set at BIO 2018 – by participating in over 48,500 partnering meetings at this year’s convention. Gaining access to an environment that facilitates this many networking and partnering opportunities is exactly why companies like PainCareLabs look forward to attending the annual event. 

“BIO is all about deals and we were able to get our first purchase order just 7 days after the show,” said Baxter. “We would definitely attend again!”

Tara Lorenz, Senior Marketing Manager at Recro Gainesville , also expressed her company’s enthusiasm for the event and the support that was provided to Georgia organizations. 

“Many attendees were excited to see the State of Georgia represented at BIO 2019 and approached our booth to learn about Recro Gainesville’s capabilities as a Contract Drug Manufacturing Organization,” stated Lorenz.  

“By attending and exhibiting at events such as BIO 2019, we have the opportunity to learn and reflect on how recent innovations and advances in technology could have a global impact to address unmet medical needs and increase the number of approved orphan drugs and rare disease medications worldwide.”

Lorenz also elaborated on the value of events like BIO that bring together large groups of innovators who don’t normally have the opportunity to collaborate on a day-to-day basis.

“This kind of collaboration is so instrumental for sharing best practices and fostering advancement in healthcare,” she explained. “These new conversations that develop into trusted relationships could advance a new molecule all the way to FDA approval and result in novel therapies for future generations. Events like this one truly help set the stage for manufacturing and commercializing new life saving medications for patients.” 

Georgia Bio loved the opportunity to partner with the State of Georgia on the Georgia Pavilion to help drive growth for our members and Georgia’s biosciences industry at the BIO International Convention, and we are looking forward to BIO 2020 in San Diego! For more information on Georgia Bio and our mission, visit www.gabio.org or follow us on Twitter @Georgia_Bio

By Maria Thacker Goethe October 22, 2025
“Evolving FTC and DOJ policies leave investors and innovators navigating a cautious M&A landscape
October 6, 2025
Atlanta, GA — October 6 — Georgia Life Sciences today announced the launch of Vitals, a new podcast series developed in partnership with Cloudcast Media, a leader in branded podcast production. The series will spotlight the people, ideas, and innovations shaping the future of Georgia’s rapidly growing life sciences sector. Hosted by Georgia Life Sciences’ CEO, Maria Thacker Goethe, Vitals will feature in-depth conversations with scientists, entrepreneurs, investors, educators, policymakers, and patient advocates. Each episode will explore the challenges and opportunities facing Georgia’s life sciences ecosystem—spanning biopharma, medical technology, digital health, and advanced manufacturing. “Vitals gives us a powerful platform to showcase the remarkable work happening within our state,” said Maria Thacker Goethe. “By sharing these stories, we’re highlighting not only groundbreaking science but also the collaboration and talent that make Georgia such a vibrant hub for health innovation.” Cloudcast Media, known for its expertise in storytelling and high-quality podcast production, will bring industry insights and technical support to ensure the series reaches audiences across Georgia and beyond. “We’re proud to partner with Georgia Life Sciences on Vitals,” said Charles Parisi, Founder and CEO of Cloudcast. “This series will elevate the voices of innovators who are advancing science, improving patient outcomes, and building Georgia’s reputation as a global life sciences leader. We are very excited that Cloudcast Atlanta can play a role in supporting Maria and the impactful work of Georgia Life Sciences.” The first episode of Vitals launched today and is available on Apple Podcasts, Spotify, and other major streaming platforms, as well as through the Georgia Life Sciences website.
October 1, 2025
September 30, 2025 WASHINGTON, D.C. – John F. Crowley, President and CEO of the Biotechnology Innovation Organization (BIO) released the following statement on Most Favored Nation policies: "For too many years, Americans have subsidized the research and development necessary to bring newer and better medicines to patients around the world. As we saw with defense spending and NATO, the solution is not to weaken a strategically important American industry, but for other countries to pay their fair share. “Today’s announcement in the Oval Office highlights the problems with a drug delivery system where half of the cost of innovative medicines goes to middlemen and distributors, and where the supply chain distorts prices paid by the American people. We support a new framework that addresses the cost of medicines by simplifying the system - and making medicines directly available to patients. “But importing socialist price controls through most-favored nation policies fundamentally does not address the imbalance in international pricing for innovative medicines. MFN will not lower the out-of-pocket prices that most Americans pay for medicines. Even worse, it will jeopardize the entrepreneurial spirit and deter the capital necessary for a vibrant and essential American biotechnology industry to thrive and may cause most harm to small and midsize biotech companies, which are responsible for discovering more than half of all new treatments. “Without these biotech innovators and a free-market system, we risk slower scientific progress, decreased access to new medicines, compromised national security, fewer American jobs and perhaps most tragically, a diminished hope for those suffering with illness and disease. There are much better ways to address this problem than MFN.” ###
MORE POSTS